Waters에 대한 매도 수량은 투자자에게 Waters의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Waters (NYSE:WAT) 주식, 공매도 수량 보고

Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.

EXEL

GRMN

MBLY

PAYC

RBLX

RDDT

SNAP

TEAM

TWLO

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 레딧(NYSE:RDDT)의 주가는 회사가 3분기 실적을 보고하고 예상보다 높은 4분기 매출 지침을 발표한 후 38.86% 상승했으며 많은 분석가들이 주가 예측을 상향했다.

레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)

Waters Corp

AMD MSCI WTR ESG ETF

Energous Corp

AMND MSCI WTR D ETF

Deutsche Bank analyst Justin Bowers maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $310 to $325.

News

Price Target

Analyst Ratings

Deutsche Bank Maintains Hold on Waters, Raises Price Target to $325

Bernstein analyst Eve Burstein maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Market Perform and raises the price target from $345 to $360.

Bernstein Maintains Market Perform on Waters, Raises Price Target to $360

TD Cowen analyst Dan Brennan maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $363 to $410.

TD Cowen Maintains Hold on Waters, Raises Price Target to $410

Stifel analyst Daniel Arias maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $332 to $360.

Stifel Maintains Hold on Waters, Raises Price Target to $360

JP Morgan analyst Rachel Vatnsdal maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $340 to $380.

JP Morgan Maintains Neutral on Waters, Raises Price Target to $380

6 analysts have shared their evaluations of Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Waters, revealing an average target of $372.5, a high estimate of $415.00, and a low estimate of $330.00. Marking an increase of 9.56%, the current average surpasses the previous average price target of $340.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1730729020_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Waters is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$415.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$360.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$355.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$360.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Waters. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Waters's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Waters's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Delving into Waters's Background</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Waters: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Waters showcased positive performance, achieving a revenue growth rate of 4.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.82% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE stands out, surpassing industry averages. With an impressive ROE of 10.71%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 3.6%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.19, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 6 Ratings For Waters

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Overweight and raises the price target from $380 to $415.

Wells Fargo Maintains Overweight on Waters, Raises Price Target to $415

Barclays analyst Luke Sergott maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Underweight and raises the price target from $330 to $360.

Barclays Maintains Underweight on Waters, Raises Price Target to $360

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares jumped 38.86% after the company reported third-quarter results and issued&nbsp;Q4&nbsp;revenue&nbsp;guidance&nbsp;above estimates, and many <a href="https://www.benzinga.com//node/41631795" target="_blank" rel="noreferrer noopener">analysts raised the price forecast</a>.</li>
<li>Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) stock escalated 27.95% after the company reported third-quarter results and <a href="https://www.benzinga.com/quote/payc/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts boosted the price forecast</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 22.89% last week after the <a href="https://www.benzinga.com//node/41653083" target="_blank" rel="noreferrer noopener">company reported Q3 earnings</a> and sales that beat analyst estimates. Many analysts revised their <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) gained 22.43% after reporting better-than-expected Q3 earnings and raising its FY24 sales outlook. Many <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts also raised their price forecasts for</a> the stock.</li>
<li>Garmin Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)&nbsp;shares surged 22.11% after the company reported&nbsp;Q3 financial results <a href="https://www.benzinga.com//node/41625504" target="_blank" rel="noreferrer noopener">and raised its annual&nbsp;outlook</a>.</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) shares increased 22.07% after the company reported better-than-expected&nbsp;third-quarter results and a year-over-year increase in daily <a href="https://www.benzinga.com//node/41654520" target="_blank" rel="noreferrer noopener">active users and hours engaged</a>. Many analysts upped the <a href="https://www.benzinga.com/quote/rblx/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) stock increased 20.39% after the company reported better-than-<a href="https://www.benzinga.com//node/41639676" target="_blank" rel="noreferrer noopener">expected&nbsp;financial results</a>. Several analysts boosted the <a href="https://www.benzinga.com/quote/twlo/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares rose 19.90% after the company reported quarterly results and several analysts revised the <a href="https://www.benzinga.com//node/41633681" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Waters Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) shares gained 19.31% last week. The company reported better-than-expected Q3 earnings and raised its annual outlook.</li>
<li>Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 18.87% last week on Q1 earnings and a strong Q2 outlook. The company&#8217;s board approved a new $1.5 billion share repurchase program, and many <a href="https://www.benzinga.com/quote/team/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts boosted the stock&#8217;s price forecast</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41702898/super-micro-computer-li-auto-and-estee-lauder-are-among-top-10-large-cap-losers-last-week-oct-28-n">Super Micro Computer, Li Auto And Estee Lauder Are Among Top 10 Large Cap Losers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Shutterstock

Large Cap

Movers

Trading Ideas

Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

Wall Street rebounded Friday following Thursday&#8217;s selloff, yet midday gains were still insufficient to prevent a second consecutive weekly decline for the S&amp;P 500, currently <a href="https://www.benzinga.com/markets">down 1% for the week. </a>
Concerns over tech earnings eased after Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) outperformed expectations, restoring some risk appetite and supporting the sector rebound.
Amazon shares surged over 6%, heading for their best session since February.
The Nasdaq 100, up by 1.1%, outperformed the S&amp;P 500, up 0.8%. 
In economic data, the U.S. economy added just 12,000 jobs in October, a steep drop from the 223,000 gain in September and well below the forecast of 113,000, as hurricanes and strikes led to hiring freezes nationwide. 
Despite the weak job figures, the unemployment rate held steady at 4.1%, indicating companies chose to retain workers rather than downsize.
The ISM Manufacturing PMI signaled contraction for the seventh consecutive month in October, with the index missing estimates.
Oil prices experienced a volatile session, initially spiking on reports of an imminent retaliatory attack by Iran on Israel before pulling back as those concerns faded. Gold edged down 0.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dipped 0.3%, slipping below the $70,000 mark.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,123.15</td>
<td>1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,161.88</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,751.05</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,209.70</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $573.75.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $422.09.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.2% to $489.80.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.8% to $219.26.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 2%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), down 1.6%.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), up over 6%.</li>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), up 20%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), down 0.7%.</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), up 2.8%.</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), up 13%.</li>
<li>Dominon Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>), down 0.2%.</li>
<li>Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 6%.</li>
<li>CBOE Global Markets Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NYSE">CBOE</a>), down 2.9%.</li>
<li>Waters Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), up 17%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690576/apple-q4-results-better-than-feared-analysts-highlight-iphone-16-demand-apple-intel">Apple Q4 Results &#8216;Better-Than-Feared&#8217;: Analysts Highlight iPhone 16 Demand, Apple Intelligence Opportunity After &#8216;Rock Solid Quarter&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

CBOE

CHTR

SPDR Dow Jones Industrial Average ETF Trust

INTC

Select Sector SPDR-Consumer Discretionary

Tech Stocks Surge But S&P 500 Faces Second Weekly Decline, Amazon Rallies, Bitcoin Drops Below $70,000: What's Driving Markets Friday?

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Friday.
Shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for the <a href="https://www.benzinga.com/quote/AMZN">third quarter on Thursday</a>.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Amazon.com shares jumped 7.1% to $199.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) shares jumped 31.8% to $36.10 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 30% to $22.72 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) jumped 25.3% to $1.3145 after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) gained 19.7% to $19.52.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) rose 17.3% to $378.98 after the company reported third-quarter earnings and sales that beat analyst estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 16.5% to $96.73 following third-quarter results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 15.8% to $218.37 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 15.6% to $14.26 following better-than-expected quarterly earnings.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) gained 14.2% to $7.98. ASP Isotopes announced the pricing of public offering of common stock.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) surged 13.2% to $36.32 following better-than-expected quarterly earnings.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) gained 12% to $366.93 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 11.5% to $89.49.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 9.9% to $55.56 after the company reported better-than-expected quarterly financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 9.6% to $14.92.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) surged 8.2% to $133.01 after the company raised its FY2024 adjusted EPS guidance.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 8.1% to $130.46 following quarterly results.</li>
<li>Dorman Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) gained 7.9% to $123.05 following upbeat earnings.</li>
<li>Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) jumped 7.8% to $42.54 following third-quarter results.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) gained 7.1% to $116.21 after the company reported better-than-expected first-quarter EPS and revenues and raised its FY2025 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Intraday Update

Markets

ADMA

ASPI

DORM

GSAT

GTLS

HALO

LBRDA

PRLB

TILE

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday

WIIM

Waters shares are trading higher after the company reported Q3 earnings and sales that beat analyst estimates.

The Company now expects full-year 2024 organic constant currency sales growth to be in the range of -2.0% to -0.5%. Currency translation is expected to decrease full-year sales growth by approximately 1.5%. M&amp;A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales.&nbsp;

Guidance

Waters Corp Revises FY24 Reported Sales Growth To -0.8% To -0.2% (Prior View -2.2% To -0.7%), Adj EPS Forecast From  $11.55 - $11.65 To $11.67 - $11.87 (Est $11.60)

Waters Corp Expects Q4 Constant Currency Sales Growth To Be +5.0% To +7.0%, Adj EPS Of $3.90 - $4.10, Est $4.09

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly earnings of $2.93 per share which beat the analyst consensus estimate of $2.68 by 9.33 percent. The company reported quarterly sales of $740.30 million which beat the analyst consensus estimate of $713.02 million by 3.83 percent. This is a 4.02 percent increase over sales of $711.69 million the same period last year.

Earnings Beats

Waters Q3 2024 Adj EPS $2.93 Beats $2.68 Estimate, Sales $740.30M Beat $713.02M Estimate

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) is preparing to release its quarterly earnings on Friday, 2024-11-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Waters to report an earnings per share (EPS) of $2.68.
Anticipation surrounds Waters's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.07 in the last quarter, leading to a 4.83% increase in the share price on the following day.
Here's a look at Waters's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.56</td>
<td>2.10</td>
<td>3.55</td>
<td>2.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.63</td>
<td>2.21</td>
<td>3.62</td>
<td>2.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730383280_0.png" alt="eps graph" />
<h3>Waters Share Price Analysis</h3>
Shares of Waters were trading at $326.59 as of October 30. Over the last 52-week period, shares are up 24.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Waters</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Waters.
Waters has received a total of 4 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $365.0, the consensus suggests a potential 11.76% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Avantor, Illumina and Revvity, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Avantor, with an average 1-year price target of $28.67, implying a potential 91.22% downside.</li>
<li>As per analysts' assessments, Illumina is favoring an Neutral trajectory, with an average 1-year price target of $167.41, suggesting a potential 48.74% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Revvity, with an average 1-year price target of $135.0, indicating a potential 58.66% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for Avantor, Illumina and Revvity, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waters</td>
<td>Buy</td>
<td>-4.33%</td>
<td>$420.29M</td>
<td>10.70%</td>
</tr>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.36%</td>
<td>$581.50M</td>
<td>1.73%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-5.44%</td>
<td>$721M</td>
<td>-55.45%</td>
</tr>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>-2.45%</td>
<td>$385.51M</td>
<td>0.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Waters ranks highest in Gross Profit and Return on Equity among its peers. However, it ranks lowest in Revenue Growth. Overall, Waters is positioned in the middle compared to its peers based on the provided metrics.
<h3>Get to Know Waters Better</h3>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>A Deep Dive into Waters's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Waters's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -4.33%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.15% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's ROA stands out, surpassing industry averages. With an impressive ROA of 3.19%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Waters's debt-to-equity ratio stands notably higher than the industry average, reaching 1.48. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/WAT/earnings">To track all earnings releases for Waters visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Waters's Earnings Forecast

<ul>
<li>Waters new&nbsp;LC-MS&nbsp;grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders.</li>
<li>Novel digestion enzymes deliver complete RNA sequence coveragei&nbsp;for more confident characterization, while new LC-MS-grade reagents increase sensitivity and improve detection accuracy of RNA components.ii</li>
<li>New&nbsp;waters_connect&#x2122; MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows that reduce data processing time over manual techniques, enabling routine monitoring of key product attributes.</li>
</ul>
MILFORD, Mass., Oct. 10, 2024 /PRNewswire/ -- Waters Corporation (NYSE:&nbsp;WAT) today introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LC-MS) analysis. When used together in a workflow, these bioseparations tools help accelerate and improve the development of innovative large molecule RNA-based pharmaceuticals, such as CRISPR sgRNA and mRNA therapeutics.

Biotech

General

Waters Announces Its New Bioseparations Tools Accelerate And Improve Development Of RNA-based Vaccines And Therapies Using LC-MS Analysis

Throughout the last three months, 7 analysts have evaluated Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $354.0, with a high estimate of $415.00 and a low estimate of $300.00. This upward trend is evident, with the current average reflecting a 9.2% increase from the previous average price target of $324.17.
<img src="https://www.benzinga.com/files/images/story/2024/1728417638_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Waters among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$355.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$363.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$310.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$325.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Waters's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Waters's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Delving into Waters's Background</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Breaking Down Waters's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Waters's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -4.33%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.15%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Waters's ROE excels beyond industry benchmarks, reaching 10.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.19%, the company showcases effective utilization of assets.
Debt Management: Waters's debt-to-equity ratio surpasses industry norms, standing at 1.48. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Waters

Jefferies analyst Tycho Peterson upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Hold to Buy and raises the price target from $355 to $415.

Upgrades

Jefferies Upgrades Waters to Buy, Raises Price Target to $415

Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a In-Line and raises the price target from $335 to $355.

Evercore ISI Group Maintains In-Line on Waters, Raises Price Target to $355

Waters Corp ( ($WAT) ) has released its Q3 earnings. Here is a breakdown of the information Waters Corp presented to its investors. Waters Corporat...

Waters Corporation Reports Strong Q3 2024 Performance

What Moved Markets This Week

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), Cardina...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vir Biotechnology (VIR), Cardinal Health (CAH) and Waters (WAT)

TD Cowen analyst Daniel Brennan maintained a Hold rating on Waters (WAT – Research Report) yesterday and set a price target of $410.00. Daniel Bren...

Cautious Optimism Amid Valuation Concerns: Hold Rating for Waters Corporation

Barclays raised the firm's price target on Waters (WAT) to $360 from $330 and keeps an Underweight rating on the shares. The big earnings beat sugg...

Waters price target raised to $360 from $330 at Barclays

Wells Fargo raised the firm's price target on Waters (WAT) to $415 from $380 and keeps an Overweight rating on the shares. The Q3 beat and Q4 guide...

Waters price target raised to $415 from $380 at Wells Fargo

Stifel analyst Daniel Arias raised the firm's price target on Waters (WAT) to $360 from $332 and keeps a Hold rating on the shares. Q3 was "strong,...

Waters price target raised to $360 from $332 at Stifel

Analyst Tycho Peterson from Jefferies maintained a Buy rating on Waters (WAT – Research Report) and keeping the price target at $415.00. Tycho Pete...

Positive Growth Outlook for Waters Driven by Product Replacement Cycle and Strong Market Demand

Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Waters (WAT – Research Report), with a price target of $400.00. Puneet Souda's ...

Optimistic Growth Forecast for Waters Corporation Driven by Strategic Positioning and Industry Trends

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

APTV

GOOG

GOOGL

INCY

MSFT

QRVO

SMCI

Press Releases

Waters Corporation Schedules Second Quarter 2024 Earnings Conference Call

Waters New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Commodities

Waters Corporation (NYSE: WAT) Reports Second Quarter 2024 Financial Results

Waters Corporation Appoints Heather Knight to Board of Directors

Waters Corporation Schedules Third Quarter 2024 Earnings Conference Call

New Waters Discovery Core Rheometer Brings the Power of Rheology to Routine Quality Control Testing

Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results

Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Waters

매도 수량

Waters (NYSE:WAT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌